Syncom Formulations
13.47
-0.37(-2.67%)
Market Cap₹1,266.18 Cr
PE Ratio19.03
IndustryHealthcare
Company Performance:
1D-2.67%
1M+20.38%
6M-19.44%
1Y-23.29%
5Y+66.30%
View Company Insightsright
More news about Syncom Formulations
03Jan 26
Syncom Formulations Receives ₹1.42 Crore GST Demand Notice Including Penalty
Syncom Formulations has received a ₹1.42 crore GST demand notice including penalty for alleged ineligible input tax credits. The company plans to appeal the decision while maintaining regulatory compliance commitments.
 no imag found
22Nov 25
Syncom Formulations Acquires Mumbai Property for ₹51.70 Crore
Syncom Formulations (India) Limited has purchased a commercial property in Mumbai for ₹51.70 crore. The acquisition involves the entire 3rd floor of TradeStar building on Andheri-Kurla Road, sold by HDFC Bank Ltd. This transaction, considered material by the company, represents about 12.5% of Syncom's total assets based on FY 2025 figures. The strategic location in Andheri, a Mumbai business district, could provide operational advantages. This move may significantly impact the company's fixed asset base and indicates a commitment to long-term presence in Mumbai.
 no imag found
13Nov 25
Syncom Formulations Reports Mixed Q2 Performance with Revenue Decline and Profit Drop
Syncom Formulations (India) Limited's Q2 FY24 results show a decline in both revenue and profit compared to the previous quarter. Revenue decreased to ₹1,214.35 crore from ₹1,654.67 crore, while net profit dropped to ₹157.29 crore from ₹169.50 crore. The company's half-year revenue improved to ₹2,869.02 crore from ₹1,873.57 crore year-over-year. Basic EPS for the quarter was ₹0.18. Syncom operates in pharmaceuticals, commodity trading, and property renting segments.
 no imag found
18Aug 25
Syncom Formulations Announces Dual Leadership Resignations: CFO and Whole-time Director Step Down
Syncom Formulations (India) Limited reported the resignations of two senior executives. Shri Ankit Kedarmal Bankda stepped down as Chief Financial Officer, and Smt. Rinki Ankit Banka resigned as Director and Whole-time Director, both effective August 8, 2025. The company disclosed this information on August 18, 2025, citing internal processing and settlement formalities as reasons for the delayed announcement. The resignations were reported in compliance with SEBI regulations.
 no imag found
08Aug 25
Syncom Formulations Reports Strong Q1 Growth with Revenue Up 34% and Net Profit Doubling
Syncom Formulations (India) Limited reported impressive Q1 financial results. Revenue from operations increased by 34% to ₹11,654.69 crore, while net profit more than doubled to ₹1,572.93 crore, marking a 106% growth. EBITDA rose by 85% to ₹2,179.44 crore, with an improved EBITDA margin of 18.70%. The company's board announced several key appointments and leadership changes, including the re-designation of Shri Kedarmal Shankarlal Bankda and the appointment of Shri Ankit Kedarmal Bankda as Chairman and Whole Time Director. The 37th AGM is scheduled for September 29.
 no imag found
20May 25
Syncom Formulations Reports Impressive Q4 Results with Soaring Profits and Revenue
Syncom Formulations announced impressive Q4 financial results. Net profit soared 159.26% year-over-year to ₹175.00 crore, up 36.72% quarter-over-quarter. Revenue reached ₹1,500.00 crore, a 104.72% increase from the previous year. The company's strong performance indicates effective business strategies and high market demand for its products.
 no imag found
19May 25
Syncom Formulations Reports Impressive Q4 Financial Results with Substantial Growth
Syncom Formulations announced impressive Q4 financial results, with revenue soaring 104% year-over-year to ₹1,500.00 crore. Net profit surged 159% to ₹175.00 crore, while EBITDA nearly doubled to ₹175.00 crore. Despite strong overall performance, EBITDA margin slightly decreased to 11.67% from 12.02% in the previous year.
 no imag found
Syncom Formulations
13.47
-0.37
(-2.67%)
1 Year Returns:-23.29%
Industry Peers
Sun Pharmaceutical
1,620.40
(-3.55%)
Divis Laboratories
6,361.50
(-0.27%)
Torrent Pharmaceuticals
4,117.20
(-0.72%)
Dr Reddys Laboratories
1,317.10
(-1.04%)
Lupin
2,296.10
(-1.93%)
Cipla
1,295.00
(-0.83%)
Mankind Pharma
2,267.40
(-1.11%)
Zydus Life Science
927.40
(-2.00%)
Aurobindo Pharma
1,413.80
(-1.50%)
Glenmark Pharmaceuticals
2,299.50
(-1.52%)